Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
Vaccines|August 28, 2021
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor ActivityLouis F Chai, John C Hardaway, Kara R Heatherton, et al.Surgery|July 5, 2020
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse modelJayanth S Shankara Narayanan, Diego A Vicente, Partha Ray, et al.Clinical and Experimental Pharmacology & Physiology|February 6, 2010
Tumour-selective antivascular effects of the novel anti-mitotic compound A-318315: An in vivo rat regional haemodynamic studyJason A Segreti, Kristin A Brooks, Kennan C Marsh, et al.European Journal of Pharmacology|April 14, 2010
In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemiaAndrew J King, Jason A Segreti, Kelly J Larson, et al.The Journal of Surgical Research|December 20, 2021
Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis ModelLouis F Chai, John C Hardaway, Kara R Heatherton, et al.Pain|April 5, 2002
Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitorMichael F Jarvis, Haixia Yu, Steve McGaraughty, et al.Journal of Cardiovascular Pharmacology|July 27, 2005
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogsRyan M Fryer, Pamela A Rakestraw, Lee C Preusser, et al.The Journal of Pharmacology and Experimental Therapeutics|March 4, 2009
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibitionPamela H Franklin, Patricia N Banfor, Paul Tapang, et al.Journal for Immunotherapy of Cancer|July 22, 2024
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastasesChandra C Ghosh, Lauren Cournoyer, Yujia Liu, et al.Molecular Cancer Research : MCR|October 17, 2008
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaksXuesong Liu, Yan Shi, Ran Guan, et al.Pageof 7